Litcius/Paper detail

Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series

Ali Tabatabai, Joseph Rabin, Jay Menaker, Ronson J. Madathil, Samuel M. Galvagno, Ashley Menne, Jonathan H. Chow, Alison Grazioli, Daniel Herr, Kenichi A. Tanaka, Thomas M. Scalea, Michael Mazzeffi

2020A&A Practice47 citationsDOIOpen Access PDF

Abstract

Critically ill patients with coronavirus disease 2019 (COVID-19) have been observed to be hypercoagulable, but the mechanisms for this remain poorly described. Factor VIII is a procoagulant factor that increases during inflammation and is cleaved by activated protein C. To our knowledge, there is only 1 prior study of factor VIII and functional protein C activity in critically ill patients with COVID-19. Here, we present a case series of 10 critically ill patients with COVID-19 who had severe elevations in factor VIII activity and low normal functional protein C activity, which may have contributed to hypercoagulability.

Topics & Concepts

Critically illMedicineCoronavirus disease 2019 (COVID-19)Protein CCoronavirusDiseaseInflammationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineGastroenterologyImmunologyInfectious disease (medical specialty)COVID-19 Clinical Research StudiesBlood Coagulation and Thrombosis MechanismsHeparin-Induced Thrombocytopenia and Thrombosis
Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series | Litcius